Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
15.35
+0.08 (0.52%)
Aug 6, 2026, 4:00 PM EDT - Market closed
Contineum Therapeutics Employees
Contineum Therapeutics had 51 employees as of December 31, 2025. The number of employees increased by 10 or 24.39% compared to the previous year.
Employees
51
Change (1Y)
10
Growth (1Y)
24.39%
Revenue / Employee
n/a
Profits / Employee
-$1,128,588
Market Cap
577.48M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 51 | 10 | 24.39% |
| Dec 31, 2024 | 41 | 10 | 32.26% |
| Dec 31, 2023 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 485 |
| Arvinas | 246 |
| 4D Molecular Therapeutics | 196 |
| CorMedix | 191 |
| MapLight Therapeutics | 133 |
| Adlai Nortye | 109 |
| Artiva Biotherapeutics | 106 |
| Silence Therapeutics | 88 |
CTNM News
- 6 days ago - Contineum initiated with an Outperform at LifeSci Capital - TheFly
- 7 days ago - Contineum reports Q2 EPS (40c), consensus (45c) - TheFly
- 7 days ago - Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones - Business Wire
- 7 days ago - Contineum Therapeutics Earnings release: Q2 2026 - Filings
- 7 days ago - Contineum Therapeutics Quarterly report: Q2 2026 - Filings
- 5 weeks ago - Contineum publishes manuscript on PIPE-791 in Journal of Medicinal Chemistry - TheFly
- 5 weeks ago - Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry - Business Wire
- 2 months ago - Contineum Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts